Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cytokinetics, Incorporated CYTK
$37.29
-$0.53 (-1.43%)
На 18:00, 12 мая 2023
+62.81%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3612823665.00000000
-
week52high
55.80
-
week52low
32.96
-
Revenue
94588000
-
P/E TTM
-9
-
Beta
0.79826900
-
EPS
-4.28000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 05 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| Piper Sandler | Overweight | Overweight | 10 июн 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Mizuho | Buy | Buy | 16 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 03 окт 2022 г. |
| UBS | Buy | 11 окт 2022 г. | |
| Needham | Buy | Buy | 23 дек 2022 г. |
| Truist Securities | Buy | 20 дек 2022 г. | |
| UBS | Neutral | Neutral | 15 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 15 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Blum Robert I | D | 145691 | 10000 | 17 янв 2023 г. |
| Blum Robert I | D | 406412 | 10000 | 17 янв 2023 г. |
| Blum Robert I | A | 416412 | 10000 | 17 янв 2023 г. |
| Malik Fady Ibraham | D | 156589 | 4000 | 12 янв 2023 г. |
| Blum Robert I | D | 155691 | 10000 | 04 янв 2023 г. |
| Blum Robert I | D | 406412 | 10000 | 04 янв 2023 г. |
| Blum Robert I | A | 416412 | 10000 | 04 янв 2023 г. |
| Harrington Robert Arthur | A | 5253 | 253 | 03 янв 2023 г. |
| Wysenski Nancy | A | 11522 | 126 | 03 янв 2023 г. |
| WIERENGA WENDALL | A | 12533 | 253 | 03 янв 2023 г. |
Новостная лента
Cytokinetics, Incorporated (CYTK) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 23:20
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Stuart Kupfer - Senior Vice President & Chief Medical Officer Andrew Callos - Executive Vice President & Chief Commercial Officer Robert Wong - Vice President & Chief Accounting Officer Ching Jaw - Senior Vice President & Chief Financial Officer Conference Call Participants Srikripa Devarakonda - Truist Salim Syed - Mizuho Tessa Romero - JPMorgan Charles Duncan - Cantor Fitzgerald Yasmeen Rahimi - Piper Sandler Akash Tewari - Jefferies Jeff Hung - Morgan Stanley Jason Zemansky - Bank of America Jason Butler - JMP Securities Rohit Bhasin - Needham & Co. Omari Baruti - Goldman Sachs Ash Verma - UBS Dane Leone - Raymond James Justin Kim - Oppenheimer Operator Good afternoon and welcome ladies and gentlemen to Cytokinetics' First Quarter 2023 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode.
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:02
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.02 per share a year ago.
Cytokinetics to Announce First Quarter Results on May 4, 2023
GlobeNewsWire
20 апр 2023 г. в 16:00
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks
Zacks Investment Research
10 апр 2023 г. в 13:41
Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.
Cytokinetics to Participate in Upcoming Investor Conferences
GlobeNewsWire
06 мар 2023 г. в 16:00
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: